A genetic variant in primary miR-378 is associated with risk and prognosis of hepatocellular carcinoma in a Chinese population

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  An, Jiaze ^a   Liu, Jibin ^b   Liu, Li ^c   Liu, Yao ^d   Pan, Yun ^c   Huang, Mingde ^c   Qi, Fuzhen ^c   Wen, Juan ^c   Xie, Kaipeng ^c   Ma, Hongxia ^c   Shen, Hongbing ^c   Hu, Zhibin ^c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b NANTONG TUMOR HOSPITAL   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 378; UNCLASSIFIED DRUG; MIRN378 MICRORNA, HUMAN;

ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; REPORTER GENE; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; VIRUS IDENTIFICATION; ALLELE; GENETIC PREDISPOSITION; GENETICS; HEPATITIS B; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; MULTIVARIATE ANALYSIS; PROGNOSIS; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; SURVIVAL; TUMOR CELL LINE; VIROLOGY;

ALLELES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS B; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MICRORNAS; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84899688689     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093707     Document Type: Article

References (42)

1. He J, Gu D, Wu X, Reynolds K, Duan X, et al. (2005) Major causes of death among men and women in China. N Engl J Med 353: 1124-1134. (Pubitemid 41317435)
2. Zhu ZZ, Cong WM (2003) Roles of hepatitis B virus and hepatitis C virus in hepato-carcinogenesis. Zhonghua Gan Zang Bing Za Zhi 11: 574-576.
3. Kuper H, Tzonou A, Kaklamani E, Hsieh CC, Lagiou P, et al. (2000) Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 85: 498-502. (Pubitemid 30075127)
4. Chuang SC, La Vecchia C, Boffetta P (2009) Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett 286: 9-14.
5. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576. (Pubitemid 46890874)
6. Testoni B, Schinzari V, Guerrieri F, Gerbal-Chaloin S, Blandino G, et al. (2011) p53-paralog DNp73 oncogene is repressed by IFN a/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor. Oncogene 30: 2670-8.
7. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM (2010) Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy. Annu Rev Med 61: 317-28.
8. Tang J, Guo YS, Zhang Y, Yu XL, Li L, et al. (2012) CD147 induces UPR to inhibit apoptosis and chemosensitivity by increasing the transcription of Bip in hepatocellular carcinoma. Cell Death Differ 19: 1779-90.
9. Li Q, Gao Y, Jia Z, Mishra L, Guo K, et al. (2012) Dysregulated Krüppel-like factor 4 and vitamin D receptor signaling contribute to progression of hepatocellular carcinoma. Gastroenterology 143: 799-810.
10. Marquardt JU, Fischer K, Baus K, Kashyap A, Ma S, et al. (2013) Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology 58: 1054-64.
11. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866. (Pubitemid 44629897)
12. Hu Z, Chen J, Tian T, Zhou X, Gu H, et al. (2008) Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 118: 2600-2608. (Pubitemid 351949787)
13. Hu Z, Shu Y, Chen Y, Chen J, Dong J, et al. (2011) Genetic Polymorphisms in the Precursor MicroRNA Flanking Region and Non-Small Cell Lung Cancer Survival. Am J Respir Crit Care Med 183: 641-648.
14. Xu Y, Liu L, Liu J, Zhang Y, Zhu J, et al. (2011) A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 128: 412-417.
15. Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, et al. (2011) MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. Gastroenterology 140: 1618-1628.
16. Hou J, Lin L, Zhou W, Wang Z, Ding G, et al. (2011) Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19: 232-243.
17. Li J, Wang Y, Yu W, Chen J, Luo J (2011) Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 406: 70-73.
18. Gao P, Wong CC, Tung EK, Lee JM, Wong CM, et al. (2010) Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol 54(6):1177-84.
19. Lee DY, Deng Z, Wang CH, Yang BB (2007) MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A 104: 20350-20355.
20. Urbich C, Kuehbacher A, Dimmeler S (2008) Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 79: 581-588.
21. Song G, Sharma AD, Roll GR, Ng R, Lee AY, et al. (2010) MicroRNAs control hepatocyte proliferation during liver regeneration. Hepatology 51: 1735-1743.
22. Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, et al. (2010) MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol 23: 1229-1234.
23. Guo J, Miao Y, Xiao B, Huan R, Jiang Z, et al. (2009) Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol 24: 652-657.
24. Wang P, Fu T, Wang X, Zhu W (2010) Primary, study of miRNA expression pattens in laryngeal carcinoma by microarray. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 24: 535-538.
25. Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, et al. (2010) Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis 11: 50-54.
26. Yao Y, Suo AL, Li ZF, Liu LY, Tian T, et al. (2009) MicroRNA profiling of human gastric cancer. Mol Med Report 2: 963-970.
27. Hu L, Zhai X, Liu J, Chu M, Pan S, et al. (2011) Genetic variants in HLA-DP/DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development. Hepatology 55: 1426-31.
28. Xie K, Liu J, Zhu L, Liu Y, Pan Y, et al. (2013) A potentially functional polymorphism in the promoter region of let-7 family is associated with survival of hepatocellular carcinoma. Cancer Epidemiol 37: 998-1002.
29. Gómez-Rodríguez R, Romero-Gutiérrez M, Artaza-Varasa T, González-Frutos C, Ciampi-Dopazo JJ, et al. (2012) The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma. Rev Esp Enferm Dig 104: 298-304.
30. Eichner LJ, Perry MC, Dufour CR, Bertos N, Park M, et al. (2010) miR-378 mediates metabolic shift in breast cancer cells via the PGC-1beta/ERRgamma transcriptional pathway. Cell Metab 12: 352-361.
31. Mohri T, Nakajima M, Fukami T, Takamiya M, Aoki Y, et al. (2010) Human CYP2E1 is regulated by miR-378. Biochem Pharmacol 79: 1045-1052.
32. Koop DR (1992) Oxidative and reductive metabolism by cytochrome P4502E1. FASEB J 6: 724-30.
33. Ramaiah SK, Apte U, Mehendale HM (2001) Cytochrome P4502E1 induction increases thioacetamide liver injury in diet restricted rats. Drug Metabolic Disopos 29: 1088-1095. (Pubitemid 32660526)
34. Kang JS, Wanibuchi H, Morimura K, Gonzalez FJ, Fukushima S (2007) Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis in vivo. Cancer Res 67: 11141-11146. (Pubitemid 350248538)
35. McCarver DG, Byun R, Hines RN, Hichme M, Wegenek W (1998) A genetic polymorphism in the regulatory sequences of human Cyp2E1: association with increased chloroxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol Appl Pharmacol 152: 276-281. (Pubitemid 28498696)
36. Gao Y, He Y, Ding J, Wu K, Hu B, et al. (2009) An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 39 untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis 30: 2064-2069.
37. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872. (Pubitemid 350138099)
38. Choi SJ, Oba T, Callander NS, Jelinek DF, Roodman GD (2003) AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma. Blood 101: 3778-3783. (Pubitemid 36857846)
39. Antonson P, Stellan B, Yamanaka R, Xanthopoulos KG (1996) A novel human CCAAT/enhancer binding protein gene, C/EBPepsilon, is expressed in cells of lymphoid and myeloid lineages and is localized on chromosome 14q11.2 close to the T-cell receptor alpha/delta locus. Genomics 35: 30-38. (Pubitemid 26236148)
40. Blackwood EM, Eisenman RN (1991) Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251: 1211-1217. (Pubitemid 21926213)
41. Mäkelä TP, Koskinen PJ, Västrik I, Alitalo K (1992) Alternative forms of Max as enhancers or suppressors of Myc-ras cotransformation. Science 256: 373-377.
42. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-2.